Bionano Genomics, Inc. (NASDAQ:BNGO) Given Average Recommendation of “Hold” by Analysts

Shares of Bionano Genomics, Inc. (NASDAQ:BNGO) have been given a consensus rating of “Hold” by the four research firms that are currently covering the company, MarketBeat.com reports. Three investment analysts have rated the stock with a hold recommendation and one has issued a buy recommendation on the company. The average 12-month target price among analysts that have issued a report on the stock in the last year is $7.00.

Several brokerages recently issued reports on BNGO. Wall Street Zen raised shares of Bionano Genomics from a “sell” rating to a “hold” rating in a report on Saturday, May 24th. HC Wainwright initiated coverage on shares of Bionano Genomics in a report on Wednesday, April 9th. They set a “buy” rating and a $10.00 price objective on the stock. Finally, Scotiabank increased their target price on shares of Bionano Genomics from $1.00 to $4.00 and gave the stock a “sector perform” rating in a research report on Wednesday, April 2nd.

Bionano Genomics Price Performance

Shares of Bionano Genomics stock opened at $3.26 on Wednesday. Bionano Genomics has a twelve month low of $2.68 and a twelve month high of $52.20. The company has a quick ratio of 1.34, a current ratio of 1.70 and a debt-to-equity ratio of 0.07. The company has a 50-day simple moving average of $3.88 and a two-hundred day simple moving average of $6.69. The stock has a market capitalization of $10.95 million, a price-to-earnings ratio of -0.02 and a beta of 2.27.

Bionano Genomics (NASDAQ:BNGO) last issued its earnings results on Wednesday, May 14th. The company reported ($1.15) EPS for the quarter, beating the consensus estimate of ($3.49) by $2.34. The company had revenue of $6.46 million during the quarter, compared to analysts’ expectations of $6.25 million. Bionano Genomics had a negative net margin of 294.05% and a negative return on equity of 125.75%.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in BNGO. Carret Asset Management LLC boosted its holdings in shares of Bionano Genomics by 39.9% during the 4th quarter. Carret Asset Management LLC now owns 119,000 shares of the company’s stock valued at $34,000 after buying an additional 33,945 shares in the last quarter. XTX Topco Ltd purchased a new position in Bionano Genomics in the 4th quarter worth about $45,000. Renaissance Technologies LLC purchased a new stake in shares of Bionano Genomics during the 4th quarter valued at about $46,000. Jane Street Group LLC bought a new position in shares of Bionano Genomics during the 4th quarter valued at approximately $118,000. Finally, Everstar Asset Management LLC purchased a new stake in Bionano Genomics during the 1st quarter valued at approximately $126,000. Institutional investors own 11.35% of the company’s stock.

About Bionano Genomics

Bionano Genomics, Inc provides genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight DNA.